Impact of NAFLD on the Incidence of Cardiovascular Diseases in a Primary Care Population in Germany

被引:78
作者
Labenz, Christian [1 ,2 ]
Huber, Yvonne [1 ,2 ]
Michel, Maurice [1 ,2 ]
Nagel, Michael [1 ,2 ]
Galle, Peter R. [1 ,2 ]
Kostev, Karel [3 ]
Schattenberg, Joern M. [1 ,2 ]
机构
[1] Johannes Gutenberg Univ Mainz, Dept Internal Med 1, Univ Med Ctr, Langenbeckstr 1, D-55131 Mainz, Germany
[2] Johannes Gutenberg Univ Mainz, Metab Liver Res Program, Univ Med Ctr, Mainz, Germany
[3] IQVIA, Epidemiol, Frankfurt, Germany
关键词
Stroke; Myocardial infarction; NASH; NAFLD; Atrial fibrillation; Cardiovascular disease; Metabolic syndrome; FATTY LIVER-DISEASE; NONALCOHOLIC STEATOHEPATITIS; FIBROSIS STAGE; RISK; ASSOCIATION; MORTALITY; OBESITY; HEALTH; US;
D O I
10.1007/s10620-019-05986-9
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background Patients with NAFLD are considered at a high risk of cardiovascular events due to underlying metabolic risk factors. Currently, data related to the impact of NAFLD on cardiovascular risk in the general population are lacking. Aims The aim of this study was to investigate the role of NAFLD on risk of myocardial infarction (MI), coronary heart disease (CHD), atrial fibrillation (AF), and stroke in primary care in Germany. Methods The study included patients diagnosed with NAFLD in primary care between 2010 and 2015. NAFLD cases (n = 22,048) were matched to a cohort without NAFLD (n = 22,048) based on age, sex, treating physician, type 2 diabetes, arterial hypertension, and hyperlipidemia. The primary outcome of the study was the incidence of MI, CHD, AF, and stroke. Results Within 10 years of the index date, 12.8% of patients with NAFLD and 10.0% of controls were diagnosed with CHD (p < 0.001). Additionally, frequency of MI was significantly higher in NAFLD (2.9% vs. 2.3%, p < 0.001). On regression analysis, HR for incidence of MI was 1.34 (p = 0.003) in all NAFLD patients and 1.35 (p = 0.013) for men. Incidence of AF was significantly higher in patients with NAFLD. On regression analysis, HR for incidence of AF was 1.15 (p = 0.005). NAFLD was not associated with a higher incidence of stroke (HR 1.09, p = 0.243). Conclusions NAFLD constitutes an independent risk factor for CHD, MI, and AF in primary care in Germany. Identification of patients with NAFLD in primary care will allow specifically managing and modifying underlying risk factors to improve the overall prognosis.
引用
收藏
页码:2112 / 2119
页数:8
相关论文
共 35 条
  • [1] Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts
    Alexander, Myriam
    Loomis, A. Katrina
    van der Lei, Johan
    Duarte-Salles, Talita
    Prieto-Alhambra, Daniel
    Ansell, David
    Pasqua, Alessandro
    Lapi, Francesco
    Rijnbeek, Peter
    Mosseveld, Mees
    Waterworth, Dawn M.
    Kendrick, Stuart
    Sattar, Naveed
    Alazawi, William
    [J]. BMC MEDICINE, 2019, 17 (1)
  • [2] [Anonymous], 2004, DTSCH ARZTEBL
  • [3] Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis
    Anstee, Quentin M.
    Targher, Giovanni
    Day, Christopher P.
    [J]. NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2013, 10 (06) : 330 - 344
  • [4] NAFLD: A multisystem disease
    Byrne, Christopher D.
    Targher, Giovanni
    [J]. JOURNAL OF HEPATOLOGY, 2015, 62 : S47 - S64
  • [5] Increased Risk of Mortality by Fibrosis Stage in Nonalcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis
    Dulai, Parambir S.
    Singh, Siddharth
    Patel, Janki
    Soni, Meera
    Prokop, Larry J.
    Younossi, Zobair
    Sebastiani, Giada
    Ekstedt, Mattias
    Hagstrom, Hannes
    Nasr, Patrik
    Stal, Per
    Wong, Vincent Wai-Sun
    Kechagias, Stergios
    Hultcrantz, Rolf
    Loomba, Rohit
    [J]. HEPATOLOGY, 2017, 65 (05) : 1557 - 1565
  • [6] Fibrosis Stage Is the Strongest Predictor for Disease-Specific Mortality in NAFLD After Up to 33 Years of Follow-Up
    Ekstedt, Mattias
    Hagstrom, Hannes
    Nasr, Patrik
    Fredrikson, Mats
    Stal, Per
    Kechagias, Stergios
    Hultcrantz, Rolf
    [J]. HEPATOLOGY, 2015, 61 (05) : 1547 - 1554
  • [7] Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030
    Estes, Chris
    Anstee, Quentin M.
    Teresa Arias-Loste, Maria
    Bantel, Heike
    Bellentani, Stefano
    Caballeria, Joan
    Colombo, Massimo
    Craxi, Antonio
    Crespo, Javier
    Day, Christopher P.
    Eguchi, Yuichiro
    Geier, Andreas
    Kondili, Loreta A.
    Kroy, Daniela C.
    Lazarus, Jeffrey V.
    Loomba, Rohit
    Manns, Michael P.
    Marchesini, Giulio
    Nakajima, Atsushi
    Negro, Francesco
    Petta, Salvatore
    Ratziu, Vlad
    Romero-Gomez, Manuel
    Sanyal, Arun
    Schattenberg, Joern M.
    Tacke, Frank
    Tanaka, Junko
    Trautwein, Christian
    Wei, Lai
    Zeuzem, Stefan
    Razavi, Homie
    [J]. JOURNAL OF HEPATOLOGY, 2018, 69 (04) : 896 - 904
  • [8] Non-alcoholic fatty liver disease and cardiovascular risk: Pathophysiological mechanisms and implications
    Francque, Sven M.
    van der Graaff, Denise
    Kwanten, Wilhelmus J.
    [J]. JOURNAL OF HEPATOLOGY, 2016, 65 (02) : 425 - 443
  • [9] Mortality Risk Detected by Atherosclerotic Cardiovascular Disease Score in Patients With Nonalcoholic Fatty Liver Disease
    Golabi, Pegah
    Fukui, Natsu
    Paik, James
    Sayiner, Mehmet
    Mishra, Alita
    Younossi, Zobair M.
    [J]. HEPATOLOGY COMMUNICATIONS, 2019, 3 (08) : 1050 - 1060
  • [10] Golabi Pegah, 2019, Clin Diabetes, V37, P65, DOI 10.2337/cd18-0026